MIFOMELATIDE FOR CANCER CACHEXIA

Cancer cachexia drug mifomelatide is in a Phase 2 trial

Mifomelatide targets the melanocortin system to prevent unintentional weight loss in patients with advanced cancer.

Mifomelatide, our most advanced product candidate, is an MC3R/MC4R dual antagonist being evaluated in a Phase 2 clinical study to prevent and treat cachexia in patients with advanced cancers.

Cachexia is a devastating wasting syndrome that can hinder patients’ ability to withstand chemotherapy and impact survival.

There are currently no U.S. FDA-approved drugs for the treatment of cachexia.​

50% of patients with cancer are affected by cachexia each year.1
Up to 30% of deaths in patients with cancer are caused by cachexia.2

Mifomelatide Highlights

1

Broad applicability across indications

Mifomelatide targets a conserved biological system at the root of all forms of cachexia, whether caused by cancer or other underlying chronic diseases

2

Safe in healthy adults

Phase 1 trial participants did not experience treatment-related adverse events3

3

Weight gain observed in Phase 1

Healthy adults taking mifomelatide gained 1.1 kg compared to placebo in just 5 days3

4

Phase 2 clinical trial enrolling

The Paradox trial is enrolling patients with newly diagnosed unresectable, locally advanced or metastatic colorectal cancer

1. Mariean et al. Cancers (Basel), 2023, 15, 5590.
2. Han et al. EJNMMI Res., 2021, 11, 94.
3. Qi et al. J Clin Oncol., 2023, 41, e15195.